

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 20, 2015

Sucampo Pharmaceuticals, Inc.

---

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

---

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4520 East-West Highway, 3<sup>rd</sup> Floor  
Bethesda, Maryland

20814

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

On March 2, 2015, Sucampo Pharmaceuticals, Inc. (“Company”) will make a corporate update presentation at the 2015 Cowen and Company Healthcare Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the Conference. The slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K and include the revenue treatment of the \$14 million upfront payment received in the 4<sup>th</sup> quarter as a result of the execution of the License, Development, Commercialization and Supply Agreement for Lubiprostone by and between Takeda Pharmaceuticals International GmbH and Sucampo AG dated October 17, 2014.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

## (d) Exhibits

- 99.1 The corporate update presentation slides dated March 2, 2015.
  - 99.2 Press Release issued by the Company on February 22, 2015.
-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: February 22, 2015

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp

Title: EVP, Chief Legal Officer and Corporate  
Secretary

# Sucampo Pharmaceuticals, Inc. 2015 Cowen and Company Healthcare Conference

March 2, 2015

**Peter Greenleaf**  
Chief Executive Officer



# Forward-Looking Statements

This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; the ability of Sucampo to develop and commercialize existing and pipeline products; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities Exchange Commission (SEC) on March 12, 2014 and the Form 10-Q as filed with the SEC on November 7, 2014.


































# Investment Highlights

- Lead product with differentiated profile in an attractive market with a large unmet need
- Blue chip partnerships provide global reach and drive outsized revenue growth
- Multiple levers available to drive sustainable long term growth
- Robust product pipeline that will build on a strong foundation
- Well-defined lifecycle management strategy maximizes franchise value
- Strong financial performance with robust balance sheet and cash position
- Deep management bench with proven experience in new product development

# Clear Strategy to Methodically Build a Leading Bio/Pharma Company

	Secure	Advance	Transform
<b>Revenue &amp; Market Value</b>	<ul style="list-style-type: none"> <li>■ <b>Focus efforts and strengthen overall capabilities</b> <ul style="list-style-type: none"> <li>• Team</li> <li>• Development capability</li> </ul> </li> <li>■ <b>Secure and grow AMITIZA revenues</b> <ul style="list-style-type: none"> <li>• Efforts to ensure consistent and sustainable growth</li> <li>• Global partnerships</li> <li>• Ongoing resolution of patent litigation</li> </ul> </li> <li>■ <b>Optimize investment in current pipeline</b> <ul style="list-style-type: none"> <li>• Life cycle management (LCM)</li> <li>• Prioritize or exit programs to maximize return on investment (ongoing)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>■ <b>Address capital structure</b> <ul style="list-style-type: none"> <li>• Diversify investor base</li> </ul> </li> <li>■ <b>Continue to strengthen capability in development</b></li> <li>■ <b>Execute on pipeline opportunities</b> <ul style="list-style-type: none"> <li>• File LCM programs for regulatory approvals</li> <li>• Progress prostones in clinical development to Phase 3</li> </ul> </li> <li>■ <b>Acquire new development programs to strengthen and accelerate the pipeline</b></li> </ul>	<ul style="list-style-type: none"> <li>■ <b>Launch AMITIZA LCM programs</b></li> <li>■ <b>Launch new pipeline products</b></li> <li>■ <b>Sustainable pipeline of drug candidates with near term launch opportunities</b></li> <li>■ <b>BD – Move to more transformative deals</b></li> <li>■ <b>Execute value creation strategy</b></li> </ul>
	<b>2014</b>	<b>2015–2017</b>	<b>2018–2021</b>

# Proven and Experienced Management Team

<b>Peter Greenleaf</b> Chief Executive Officer	    
<b>Peter Kiener, D.Phil</b> Chief Scientific Officer	   
<b>Peter Lichtlen, M.D., Ph.D.</b> Chief Medical Officer	 
<b>Matthias Alder</b> Executive Vice President, Business Development & Licensing	  
<b>Max Donley</b> Executive Vice President of Human Resources	  
<b>Steven Caffé, M.D.</b> Senior Vice President, Regulatory Affairs	    
<b>Stanley Miele</b> Senior Vice President, Sales & Marketing, President, Sucampo Pharma Americas, LLC	  
<b>Silvia Taylor</b> Senior Vice President, Investor Relations and Corporate Communications	  
<b>Andrew Smith</b> Chief Financial Officer	    

Expanded Management Team with Considerable Experience in Product Development and Commercialization





# AMITIZA is a Unique and Highly-Differentiated Product


- **Most expansive label in constipation market: 3 indications, 3 patient types**
  - **CIC:** Chronic Idiopathic Constipation
  - **IBS-C:** Irritable Bowel Syndrome with Constipation
  - **OIC:** Opioid Induced Constipation in Adults (non-cancer)
- **Most experienced product: over 9M prescriptions since 2006**
- **Only product with a dual mechanism of action**
  1. Increases intestinal fluid secretion
  2. Stimulates recovery of mucosal barrier function
- **Key product characteristics**
  - Locally-acting
  - Rapid and predictable onset of action
- **Well-tolerated product with established safety profile**
  - No black box warning




# Addressing Large Market with Significant Unmet Need

Market MATTY TRx by Category thru Dec 2014


48.2 M TRx



Brand/Generic MATTY TRx thru Dec 2014



Brand TRx by Category thru Dec 2014




OTC Market: additional ~\$800M annually


# Accelerating Growth is Evidence of Compelling Value Proposition

## U.S. (Takeda)

4-week TRx annual growth rate of 12.1% is multi-year high




## Japan (Abbott)




\*Based on Management assumption of 46 capsules per TRx

# Multiple Levers Will Drive AMITIZA Outsized Growth



# New Market Opportunities

Global prevalence of constipation disorders ranges from 5-18%



**Takeda is #1 GI company world wide**  
**Takeda has rights to all markets except Japan (Abbott) and China**

\* MRP filed in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, Netherlands, and Spain; Ireland has issued marketing authorization

## Expand AMITIZA franchise through new formulation and new indication

### 1. New Formulation

- Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients
- Incremental opportunity to address the roughly 40% of adults who have difficulty swallowing pills
- Next step: Phase 3 commence 2H 2015

### 2. New Pediatric Functional Constipation Indication

- Constipation is one of the most common gastrointestinal complaints in children
- US Prevalence: 18% of pediatric population (13.5M)
- Unmet need: No FDA-approved competition for AMITIZA in pediatric population (black box warning for linaclotide and prucalopride failed in Phase 4)
- Current formulation: older children (6-17 years) who are able to take the current capsule formulation
- Alternate formulation: younger children (6 months and above)



# Pipeline



# At-A-Glance: Sucampo Pipeline

	CLINICAL FOCUS	STAGE OF CLINICAL DEVELOPMENT				TIMELINE TARGETS		
		LEAD COMPOUNDS	PHASE 1	PHASE 2	PHASE 3	NDA/MAA FILING	APPROVAL	
Lifecyle Management	Lubiprostone – Pediatric Functional Constipation (6 years-17 years)				Pivotal LPI – 2H 2015	Open-Label LPI – 2H 2015	2016*	2017*
	Lubiprostone – Alternate Formulation (Adults)				FPI – 2H 2015 LPI – 2H 2015		2H 2016*	2017*
	Lubiprostone – Alternate Formulation – Pediatric Functional Constipation (6 months- 6 years)				Pivotal FPI – 1H 2016 LPI – 1H 2017	Open-Label FPI – 1H 2016 LPI – 2H 2016	2017*	2018*
Clinical Development	Cobiprostone – Oral Mucositis		FPI – 1H 2015 LPI – 2H 2016		FPI – 2017 LPI – 2018		2018	2019
	Cobiprostone – NERD		FPI – 2H 2014 LPI – 2H 2015		FPI – 2018 LPI – 2018		2020	2021
	New Formulation Unoprostone Isopropyl – RP				Trial Ongoing Interim Data for RTU formulation 1H 2015		2021	
	New Formulation Unoprostone Isopropyl – GA						2022	

■ COMPLETED ■ IN PROGRESS / PROJECTED START

\*Pending partner discussions

# Supplementing Existing Pipeline

- ▶ **Commenced assessment of external programs**
- ▶ **Complement existing product pipeline**
- ▶ **Leverage current skills and experience of Sucampo**
- ▶ **Therapeutic areas**
- ▶ **Platform- and technology- agnostic**
- ▶ **Orphan and specialist products**

# Financials

# Key Facts and Financial Summary

## Financial Highlights for Q3 2014

Cash & Equivalents	\$106.4M
Notes Payable*	\$48.1M
Total Revenue	\$31.5M
Net Income, excluding special items	\$6.3M
EPS, excluding special items	\$0.14
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$88.5M

## Financial Highlights for Nine Months 2014

Total Revenue	\$77.7M
Net Income, excluding special items	\$8.6M
EPS, excluding special items	\$0.20
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$240.5M
Raised full year 2014 guidance*, excluding special items	Net Income \$15-20M; EPS \$0.35-0.45

\*\$14M Upfront Payment from Takeda received as part of Global Takeda Agreement. \$8M will be recognized in 4Q 2014, and the recognition of the remaining \$6M will be matched against Sucampo's committed \$6M R&D spend


\*On 11-20-14 and 12-29-14, Sucampo repaid two secured loans of ¥1.0B with MUFG Bank and The Mizuho Bank Ltd., approximating a total of \$17M. These loan repayments released the total collateralized deposits of \$26M.

# Upcoming Milestones

Event	Expected Timing
Global partnership agreement for AMITIZA	√
Updated on AMITIZA alternate formulation and PFC development	√
Filed AMITIZA (CIC and OIC) for approval in Canada	√
Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets	√
Decision made on ion channel activator program for LSS	√
Cobiprostone NERD Ph. 2 FPI	√
Cobiprostone oral mucositis Ph. 2 FPI	
Approvals for AMITIZA in additional European markets	1H 2015
Go/No Go for unoprostone in retinitis pigmentosa	
Expected MHRA decision on AMITIZA (OIC) in the U.K.	
Lubiprostone alternate formulation Ph. 3 FPI	2H 2015
Lubiprostone alternate formulation Ph. 3 LPI	
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (pivotal)	
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (open-label)	
Expected approval of AMITIZA (CIC and OIC) in Canada	
Cobiprostone NERD Ph. 2 LPI	
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (pivotal)	1H 2016
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (open-label)	
File lubiprostone alternate formulation for approval in U.S.	2H 2016
Cobiprostone oral mucositis Ph. 2 LPI	
Lubiprostone PFC (6 months – 6 years) LPI (open-label)	

# Investment Highlights

- **Lead product with differentiated profile in an attractive market with a large unmet need**
- **Blue chip partnerships provide global reach and drive outsized revenue growth**
- **Multiple levers available to drive sustainable long term growth**
- **Robust product pipeline that will build on a strong foundation**
- **Well-defined lifecycle management strategy maximizes franchise value**
- **Strong financial performance with robust balance sheet and cash position**
- **Deep management bench with proven experience in new product development**



# Q & A

## Sucampo Announces Webcast of Its Presentation at the 2015 Cowen and Company Healthcare Conference

BETHESDA, Md., Feb. 22, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 2015 Cowen and Company Healthcare Conference taking place March 2, 2015 at 1:30 PM ET.

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at <http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar>. Presentation slides will be available via the webcast links. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

### About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has one marketed product – AMITIZA<sup>®</sup> – and a pipeline of drug candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan, Switzerland and the United Kingdom. For more information, please visit [www.sucampo.com](http://www.sucampo.com).

The Sucampo logo is the registered trademark and the tagline, The Science of Innovation, is a registered trademark of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Follow us on Twitter (@Sucampo\_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Twitter LinkedIn

### Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; the ability of Sucampo to develop and commercialize existing and pipeline products; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally; the effects of competitive products on Sucampo's products; and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities and Exchange Commission on March 12, 2014 as well as its filings with the Securities and Exchange Commission on Form 10-Q and 8-K, which Sucampo incorporates by reference.

CONTACT: Silvia Taylor  
Senior Vice President,  
Investor Relations and Corporate Communications  
Sucampo Pharmaceuticals, Inc.  
1-240-223-3718  
[staylor@sucampo.com](mailto:staylor@sucampo.com)